FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses

Eli Lilly said enough to convince an FDA advisory panel that its experimental rheumatoid arthritis drug is effective in treating the inflammatory disorder. But on safety, the independent experts were not uniformly persuaded, and they voted to recommend approval only for the lower of two doses. It’s the second time the Lilly drug is up for an approval decision in the past two years.